Reza Skandari joined Imperial College Business School in 2018. He is an Assistant Professor of Health Operations in the Operations Management group and affiliated with the Centre for Health Economics & Policy Innovation. Prior to that he worked as a Senior Research Analyst at the Center for Translational and Policy Research of Chronic Diseases at the University of Chicago School of Medicine. He obtained his PhD in Management Science from the Sauder School of Business, University of British Columbia.
Reza's main research interests are in: (1) Health-care Operations Management and Analytics (2) Health-care Policy Research and Economics (3) Clinical Decision Making (4) Dynamic Programming and Stochastic Optimization.
et al., 2023, Expected health benefits of SGLT-2 inhibitors and GLP-1 receptor agonists in older adults, Mdm Policy & Practice, Vol:8, ISSN:2381-4683, Pages:1-11
et al., 2023, Revisiting the time needed to provide adult primary care, Journal of General Internal Medicine, Vol:38, ISSN:0884-8734, Pages:147-155
et al., 2022, First-line therapy for Type 2 Diabetes with sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a cost-effectiveness sStudy., Annals of Internal Medicine, ISSN:0003-4819
et al., 2022, Development and validation of a decision analytical model for posttreatment surveillance for patients with oropharyngeal carcinoma, Jama Network Open, Vol:5, ISSN:2574-3805
et al., 2021, Longer-term benefits and risks of sodium-glucose cotransporter-2 inhibitors in Type 2 diabetes: a systematic review and meta-analysis, Journal of General Internal Medicine, Vol:37, ISSN:0884-8734, Pages:439-448